Placebos in primary care? a nominal group study explicating UK GP and patient views of six theoretically plausible models of placebo practice.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
18 02 2020
Historique:
entrez: 21 2 2020
pubmed: 23 2 2020
medline: 17 2 2021
Statut: epublish

Résumé

To better understand which theoretically plausible placebogenic techniques might be acceptable in UK primary care. A qualitative study using nominal group technique and thematic analysis. Participants took part in audio-recorded face-to-face nominal groups in which the researcher presented six scenarios describing the application in primary care of theoretically plausible placebogenic techniques: (1) Withholding side effects information, (2) Monitoring, (3) General practitioner (GP) endorsement, (4) Idealised consultation, (5) Deceptive placebo pills and (6) Open-label placebo pills. Participants voted on whether they thought each scenario was acceptable in practice and discussed their reasoning. Votes were tallied and discussions transcribed verbatim. Primary care in England. 21 GPs in four nominal groups and 20 'expert patients' in five nominal groups. Participants found it hard to decide which practices were acceptable and spoke about needing to weigh potential symptomatic benefits against the potential harms of lost trust eroding the therapeutic relationship. Primary care patients and doctors felt it was acceptable to harness placebo effects in practice by patient self-monitoring (scenario 2), by the GP expressing a strongly positive belief in a therapy (scenario 3) and by conducting patient-centred, empathic consultations (scenario 4). Deceptive placebogenic practices (scenarios 1 and 5) were unacceptable to most groups. Patient and GP groups expressed a diverse range of opinions about open-label placebo pills. Attempts to harness placebo effects in UK primary care are more likely to be accepted and implemented if they focus on enhancing positive patient-centred communication and empathic relationships. Using placebos deceptively is likely to be unacceptable to both GPs and patients. Open-label placebos also do not have clear support; they might be acceptable to some doctors and patients in very limited circumstances-but further evidence, clear information and guidance would be needed.

Identifiants

pubmed: 32075826
pii: bmjopen-2019-032524
doi: 10.1136/bmjopen-2019-032524
pmc: PMC7044897
doi:

Substances chimiques

Pharmaceutical Preparations 0
Placebos 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e032524

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Neurogastroenterol Motil. 2005 Jun;17(3):332-40
pubmed: 15916620
PLoS One. 2013 May 15;8(5):e62599
pubmed: 23690944
Health (London). 2018 Sep 21;:1363459318800169
pubmed: 30238795
BMJ Open. 2017 Jun 30;7(6):e015516
pubmed: 28667217
Fam Pract. 2014 Jun;31(3):357-63
pubmed: 24736295
BMJ. 2018 Oct 2;363:k3889
pubmed: 30279235
J Evid Based Med. 2017 May;10(2):97-107
pubmed: 28452193
Lancet. 2001 Mar 10;357(9258):757-62
pubmed: 11253970
Psychiatry Res. 2015 Dec 15;230(2):300-3
pubmed: 26381184
Ann Rheum Dis. 2008 Dec;67(12):1716-23
pubmed: 18541604
PLoS One. 2013;8(3):e58247
pubmed: 23526969
Health Psychol. 2019 Dec;38(12):1128-1136
pubmed: 31556659
PLoS One. 2014 Jul 09;9(7):e101822
pubmed: 25006673
Complement Ther Med. 2013 Apr;21(2):94-7
pubmed: 23497809
PLoS One. 2018 Aug 24;13(8):e0202211
pubmed: 30142199
PLoS One. 2019 Jul 10;14(7):e0219482
pubmed: 31291326
PLoS One. 2010 Dec 22;5(12):e15591
pubmed: 21203519
Ann Intern Med. 2002 Mar 19;136(6):471-6
pubmed: 11900500
Eur Neuropsychopharmacol. 2012 Nov;22(11):770-4
pubmed: 22608298
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003974
pubmed: 20091554
PLoS One. 2014 Apr 02;9(4):e92938
pubmed: 24695272
J Fam Pract. 2000 Jul;49(7):649-54
pubmed: 10923577
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
J Med Biogr. 2005 Aug;13(3):155-61
pubmed: 16059528
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
Exp Gerontol. 2019 Apr;118:106-116
pubmed: 30658120

Auteurs

Mohana Ratnapalan (M)

Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Beverly Coghlan (B)

ACT Works Ltd, Portsmouth, UK.

Mengxin Tan (M)

Centre of Global Mental Health, London School of Hygiene and Tropical Medicine, London, London, UK.
Institute of Psychiatry, Psychology and Neuroscience, London, London, UK.

Hazel Everitt (H)

Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Adam W A Geraghty (AWA)

Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Paul Little (P)

Primary Care and Population Sciences, University of Southampton, Southampton, UK.

George Lewith (G)

Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Felicity L Bishop (FL)

Primary Care and Population Sciences, University of Southampton, Southampton, UK F.L.Bishop@soton.ac.uk.
Centre for Clinical and Community Applications of Health Psychology, University of Southampton, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH